Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine
- Author
- DESMOULIN, Franck1 ; GILARD, Véronique1 ; MALET-MARTINO, Myriam1 ; MARTINO, Robert1
[1] Groupe de Résonance Magnétique Nucléaire Biomédicale, Unité Mixte Recherche Centre National de la Recherche Scientifique 5623, Université Paul Sabatier, Toulouse, France - Source
Drug metabolism and disposition. 2002, Vol 30, Num 11, pp 1221-1229, 9 p ; ref : 38 ref
- CODEN
- DMDSAI
- ISSN
- 0090-9556
- Scientific domain
- Pharmacology drugs
- Publisher
- American Society for Pharmacology and Experimental Therapeutics, Bethesda, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Animal Anticancéreux Capécitabine Fluoropyrimidine dérivé Fluorouracil Homme In vitro In vivo Liquide biologique Métabolisme Métabolite Pharmacocinétique Promédicament Pyrimidine dérivé Rat Souris Urine Voie orale Cytidine dérivé Mammalia Rodentia Vertebrata
- Keyword (en)
- Animal Antineoplastic agent Capecitabine Fluoropyrimidine derivatives Fluorouracil Human In vitro In vivo Biological fluid Metabolism Metabolite Pharmacokinetics Prodrug Pyrimidine derivatives Rat Mouse Urine Oral administration Mammalia Rodentia Vertebrata
- Keyword (es)
- Animal Anticanceroso Capecitabina Fluoropirimidina derivado Fluorouracilo Hombre In vitro In vivo Líquido biológico Metabolismo Metabolito Farmacocinética Promedicamento Pirimidina derivado Rata Ratón Orina Vía oral Mammalia Rodentia Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14493249
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1124/dmd.30.11.1221 
https://dx.doi.org/10.1124/dmd.30.11.1221
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:9:\"\u0000*\u0000jtitle\";s:31:\"Drug metabolism and disposition\";s:9:\"\u0000*\u0000stitle\";s:18:\"Drug metab. dispos\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1221\";s:8:\"\u0000*\u0000epage\";s:4:\"1229\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-9556\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"DESMOULIN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Franck\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"GILARD, V\u00e9ronique\";i:1;s:21:\"MALET-MARTINO, Myriam\";i:2;s:15:\"MARTINO, Robert\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DMDSAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:8:\"\u0000*\u0000place\";s:12:\"Bethesda, MD\";s:6:\"\u0000*\u0000pub\";s:63:\"American Society for Pharmacology and Experimental Therapeutics\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:9:\"\u0000*\u0000jtitle\";s:31:\"Drug metabolism and disposition\";s:9:\"\u0000*\u0000stitle\";s:18:\"Drug metab. dispos\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1221\";s:8:\"\u0000*\u0000epage\";s:4:\"1229\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-9556\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"DESMOULIN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Franck\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"GILARD, V\u00e9ronique\";i:1;s:21:\"MALET-MARTINO, Myriam\";i:2;s:15:\"MARTINO, Robert\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DMDSAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:8:\"\u0000*\u0000place\";s:12:\"Bethesda, MD\";s:6:\"\u0000*\u0000pub\";s:63:\"American Society for Pharmacology and Experimental Therapeutics\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:9:\"\u0000*\u0000jtitle\";s:31:\"Drug metabolism and disposition\";s:9:\"\u0000*\u0000stitle\";s:18:\"Drug metab. dispos\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1221\";s:8:\"\u0000*\u0000epage\";s:4:\"1229\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-9556\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"DESMOULIN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Franck\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"GILARD, V\u00e9ronique\";i:1;s:21:\"MALET-MARTINO, Myriam\";i:2;s:15:\"MARTINO, Robert\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DMDSAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:8:\"\u0000*\u0000place\";s:12:\"Bethesda, MD\";s:6:\"\u0000*\u0000pub\";s:63:\"American Society for Pharmacology and Experimental Therapeutics\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:9:\"\u0000*\u0000jtitle\";s:31:\"Drug metabolism and disposition\";s:9:\"\u0000*\u0000stitle\";s:18:\"Drug metab. dispos\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1221\";s:8:\"\u0000*\u0000epage\";s:4:\"1229\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-9556\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"DESMOULIN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Franck\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"GILARD, V\u00e9ronique\";i:1;s:21:\"MALET-MARTINO, Myriam\";i:2;s:15:\"MARTINO, Robert\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DMDSAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:8:\"\u0000*\u0000place\";s:12:\"Bethesda, MD\";s:6:\"\u0000*\u0000pub\";s:63:\"American Society for Pharmacology and Experimental Therapeutics\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1124\/dmd.30.11.1221\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:9:\"\u0000*\u0000jtitle\";s:31:\"Drug metabolism and disposition\";s:9:\"\u0000*\u0000stitle\";s:18:\"Drug metab. dispos\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:2:\"30\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"1221\";s:8:\"\u0000*\u0000epage\";s:4:\"1229\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0090-9556\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"DESMOULIN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Franck\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:18:\"GILARD, V\u00e9ronique\";i:1;s:21:\"MALET-MARTINO, Myriam\";i:2;s:15:\"MARTINO, Robert\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DMDSAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:106:\"Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine\";s:8:\"\u0000*\u0000place\";s:12:\"Bethesda, MD\";s:6:\"\u0000*\u0000pub\";s:63:\"American Society for Pharmacology and Experimental Therapeutics\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
